首页> 美国卫生研究院文献>Clinical Interventions in Aging >Selective estrogen receptor modulators: tissue specificity and clinical utility
【2h】

Selective estrogen receptor modulators: tissue specificity and clinical utility

机译:选择性雌激素受体调节剂:组织特异性和临床应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Selective estrogen receptor modulators (SERMs) are a diverse group of nonsteroidal compounds that function as agonists or antagonists for estrogen receptors (ERs) in a target gene-specific and tissue-specific fashion. SERM specificity involves tissue-specific expression of ER subtypes, differential expression of co-regulatory proteins in various tissues, and varying ER conformational changes induced by ligand binding. To date, the major clinical applications of SERMs are their use in the prevention and treatment of breast cancer, the prevention of osteoporosis, and the maintenance of beneficial serum lipid profiles in postmenopausal women. However, SERMs have also been found to promote adverse effects, including thromboembolic events and, in some cases, carcinogenesis, that have proven to be obstacles in their clinical utility. In this review, we discuss the mechanisms of SERM tissue specificity and highlight the therapeutic application of well-known and emergent SERMs.
机译:选择性雌激素受体调节剂(SERM)是多种非甾体化合物,它们以靶基因特异性和组织特异性的方式充当雌激素受体(ER)的激动剂或拮抗剂。 SERM特异性涉及ER亚型的组织特异性表达,多种组织中共调节蛋白的差异表达以及配体结合引起的不同ER构象变化。迄今为止,SERMs的主要临床应用是其在预防和治疗乳腺癌,预防骨质疏松症以及维持绝经后妇女的有益血脂方面的用途。但是,还发现SERMs会促进不良反应,包括血栓栓塞事件,在某些情况下还包括致癌作用,这些已被证明是其临床应用的障碍。在这篇综述中,我们讨论了SERM组织特异性的机制,并着重介绍了众所周知的和新兴的SERMs的治疗应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号